BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37014508)

  • 21. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
    Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
    Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.
    Zhukova N; Ramaswamy V; Remke M; Pfaff E; Shih DJ; Martin DC; Castelo-Branco P; Baskin B; Ray PN; Bouffet E; von Bueren AO; Jones DT; Northcott PA; Kool M; Sturm D; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognar L; Klekner A; Cho BK; Kim SK; Wang KC; Eberhart CG; Fevre-Montange M; Fouladi M; French PJ; Kros M; Grajkowska WA; Gupta N; Weiss WA; Hauser P; Jabado N; Jouvet A; Jung S; Kumabe T; Lach B; Leonard JR; Rubin JB; Liau LM; Massimi L; Pollack IF; Shin Ra Y; Van Meir EG; Zitterbart K; Schüller U; Hill RM; Lindsey JC; Schwalbe EC; Bailey S; Ellison DW; Hawkins C; Malkin D; Clifford SC; Korshunov A; Pfister S; Taylor MD; Tabori U
    J Clin Oncol; 2013 Aug; 31(23):2927-35. PubMed ID: 23835706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials.
    Pizer BL; Clifford SC
    Br J Neurosurg; 2009 Aug; 23(4):364-75. PubMed ID: 19637007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and mutational profiles of adult medulloblastoma groups.
    Wong GC; Li KK; Wang WW; Liu AP; Huang QJ; Chan AK; Poon MF; Chung NY; Wong QH; Chen H; Chan DTM; Liu XZ; Mao Y; Zhang ZY; Shi ZF; Ng HK
    Acta Neuropathol Commun; 2020 Nov; 8(1):191. PubMed ID: 33172502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients.
    Lamont JM; McManamy CS; Pearson AD; Clifford SC; Ellison DW
    Clin Cancer Res; 2004 Aug; 10(16):5482-93. PubMed ID: 15328187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.
    Thompson EM; Hielscher T; Bouffet E; Remke M; Luu B; Gururangan S; McLendon RE; Bigner DD; Lipp ES; Perreault S; Cho YJ; Grant G; Kim SK; Lee JY; Rao AAN; Giannini C; Li KKW; Ng HK; Yao Y; Kumabe T; Tominaga T; Grajkowska WA; Perek-Polnik M; Low DCY; Seow WT; Chang KTE; Mora J; Pollack IF; Hamilton RL; Leary S; Moore AS; Ingram WJ; Hallahan AR; Jouvet A; Fèvre-Montange M; Vasiljevic A; Faure-Conter C; Shofuda T; Kagawa N; Hashimoto N; Jabado N; Weil AG; Gayden T; Wataya T; Shalaby T; Grotzer M; Zitterbart K; Sterba J; Kren L; Hortobágyi T; Klekner A; László B; Pócza T; Hauser P; Schüller U; Jung S; Jang WY; French PJ; Kros JM; van Veelen MC; Massimi L; Leonard JR; Rubin JB; Vibhakar R; Chambless LB; Cooper MK; Thompson RC; Faria CC; Carvalho A; Nunes S; Pimentel J; Fan X; Muraszko KM; López-Aguilar E; Lyden D; Garzia L; Shih DJH; Kijima N; Schneider C; Adamski J; Northcott PA; Kool M; Jones DTW; Chan JA; Nikolic A; Garre ML; Van Meir EG; Osuka S; Olson JJ; Jahangiri A; Castro BA; Gupta N; Weiss WA; Moxon-Emre I; Mabbott DJ; Lassaletta A; Hawkins CE; Tabori U; Drake J; Kulkarni A; Dirks P; Rutka JT; Korshunov A; Pfister SM; Packer RJ; Ramaswamy V; Taylor MD
    Lancet Oncol; 2016 Apr; 17(4):484-495. PubMed ID: 26976201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
    Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ;
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
    Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
    J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression.
    Korshunov A; Okonechnikov K; Stichel D; Schrimpf D; Delaidelli A; Tonn S; Mynarek M; Sievers P; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M
    Acta Neuropathol; 2022 Aug; 144(2):339-352. PubMed ID: 35771282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes.
    Sharma T; Schwalbe EC; Williamson D; Sill M; Hovestadt V; Mynarek M; Rutkowski S; Robinson GW; Gajjar A; Cavalli F; Ramaswamy V; Taylor MD; Lindsey JC; Hill RM; Jäger N; Korshunov A; Hicks D; Bailey S; Kool M; Chavez L; Northcott PA; Pfister SM; Clifford SC
    Acta Neuropathol; 2019 Aug; 138(2):309-326. PubMed ID: 31076851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and molecular stratification of disease risk in medulloblastoma.
    Gilbertson R; Wickramasinghe C; Hernan R; Balaji V; Hunt D; Jones-Wallace D; Crolla J; Perry R; Lunec J; Pearson A; Ellison D
    Br J Cancer; 2001 Sep; 85(5):705-12. PubMed ID: 11531256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid diagnosis of medulloblastoma molecular subgroups.
    Schwalbe EC; Lindsey JC; Straughton D; Hogg TL; Cole M; Megahed H; Ryan SL; Lusher ME; Taylor MD; Gilbertson RJ; Ellison DW; Bailey S; Clifford SC
    Clin Cancer Res; 2011 Apr; 17(7):1883-94. PubMed ID: 21325292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease-associated KBTBD4 mutations in medulloblastoma elicit neomorphic ubiquitylation activity to promote CoREST degradation.
    Chen Z; Ioris RM; Richardson S; Van Ess AN; Vendrell I; Kessler BM; Buffa FM; Busino L; Clifford SC; Bullock AN; D'Angiolella V
    Cell Death Differ; 2022 Oct; 29(10):1955-1969. PubMed ID: 35379950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study.
    Hill RM; Richardson S; Schwalbe EC; Hicks D; Lindsey JC; Crosier S; Rafiee G; Grabovska Y; Wharton SB; Jacques TS; Michalski A; Joshi A; Pizer B; Williamson D; Bailey S; Clifford SC
    Lancet Child Adolesc Health; 2020 Dec; 4(12):865-874. PubMed ID: 33222802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
    Park AK; Lee JY; Cheong H; Ramaswamy V; Park SH; Kool M; Phi JH; Choi SA; Cavalli F; Taylor MD; Kim SK
    BMC Cancer; 2019 Jun; 19(1):571. PubMed ID: 31185958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular pathological insights reveal a high number of unfavorable risk patients among children treated for medulloblastoma and CNS-PNET in Oslo 2005-2017.
    Niehusmann P; Stensvold E; Leske H; Pietsch T; Goschzik T; Gielen GH; Due-Tønnessen B; Frič R; Nilssen Y; Brandal P
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29736. PubMed ID: 35570402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Medulloblastoma comprises four distinct molecular variants.
    Northcott PA; Korshunov A; Witt H; Hielscher T; Eberhart CG; Mack S; Bouffet E; Clifford SC; Hawkins CE; French P; Rutka JT; Pfister S; Taylor MD
    J Clin Oncol; 2011 Apr; 29(11):1408-14. PubMed ID: 20823417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study.
    Delaidelli A; Dunham C; Santi M; Negri GL; Triscott J; Zheludkova O; Golanov A; Ryzhova M; Okonechnikov K; Schrimpf D; Stichel D; Ellison DW; von Deimling A; Kool M; Pfister SM; Ramaswamy V; Korshunov A; Taylor MD; Sorensen PH
    Clin Cancer Res; 2022 Jan; 28(1):116-128. PubMed ID: 34702771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features.
    Kool M; Koster J; Bunt J; Hasselt NE; Lakeman A; van Sluis P; Troost D; Meeteren NS; Caron HN; Cloos J; Mrsić A; Ylstra B; Grajkowska W; Hartmann W; Pietsch T; Ellison D; Clifford SC; Versteeg R
    PLoS One; 2008 Aug; 3(8):e3088. PubMed ID: 18769486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct.
    Northcott PA; Hielscher T; Dubuc A; Mack S; Shih D; Remke M; Al-Halabi H; Albrecht S; Jabado N; Eberhart CG; Grajkowska W; Weiss WA; Clifford SC; Bouffet E; Rutka JT; Korshunov A; Pfister S; Taylor MD
    Acta Neuropathol; 2011 Aug; 122(2):231-40. PubMed ID: 21681522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.